Biocon Limited has announced significant leadership changes effective April 01, 2026, following its plan to integrate Biocon Biologics. Key announcements include the resignation of MD & CEO Mr. Siddharth Mittal and Interim CFO Mr. Mukesh Kamath to transition to new roles within the Group. Mr. Shreehas Pradeep Tambe is appointed as the new MD & CEO for five years, subject to shareholder approval.
Executive Leadership Transition Approved
The Board of Directors of Biocon Limited, following its meeting on Friday, March 27, 2026, approved several crucial leadership changes in line with the planned integration of Biocon Biologics Limited (BBL). These changes are set to take effect from April 01, 2026.
Change in CEO and Managing Director
The Board accepted the resignation of Mr. Siddharth Mittal (DIN: 03230757) as Chief Executive Officer and Managing Director, effective close of business hours on March 31, 2026, to assume another leadership role within the Biocon Group. He will also cease to be a Key Managerial Personnel (KMP).
Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of Mr. Shreehas Pradeep Tambe (DIN: 09796480), currently CEO & MD of Biocon Biologics, as an Additional Director effective April 01, 2026. He will subsequently take on the roles of Chief Executive Officer and Managing Director (KMP) for a period of five (5) years from April 01, 2026, subject to shareholder approval.
Change in Chief Financial Officer
The resignation of Mr. Mukesh Kamath as Interim Chief Financial Officer was accepted, effective March 31, 2026, as he transitions to another role in the Biocon Group. He ceases to be a KMP and Senior Management Personnel.
Mr. Kedar Narayan Upadhye, CFO of BBL, was approved as the new Chief Financial Officer (KMP and Senior Management Personnel) of the Company, effective April 01, 2026.
Appointment of Key Managerial Personnel (KMP)
Mr. Akhilesh Nand, Company Secretary of BBL, has been designated as the Head, Governance, Risk and Compliance of the Company, also effective April 01, 2026, and designated as KMP and Senior Management Personnel.
Changes in Senior Management Personnel
The Board also approved the following designations within the new organizational structure, effective April 01, 2026:
- Mr. Naveen Narayanan, Head, Global Head of HR of BBL, designated as Chief Human Resources Officer.
- Mr. Mandar Shrikant Ghatnekar, Global Head of IT & Digital Transformation of BBL, designated as Chief Technology Officer.
The following individuals were approved to cease as Senior Management Personnel effective close of business hours of March 31, 2026:
- Abhijit Zutshi (Chief Commercial Officer)
- Manoj Kumar Pananchukunnath (Chief Scientific Officer)
- Arun Kumar Gupta (Chief Operating Officer)
- Maninder Kapoor Puri (Head, Human Resources)
- Nitin Tiwari (Head, Quality)
- Vishal Nayyar (Head, Supply Chain Management)
- Amit Kaptain (Head, Commercials, API)
Authorized Personnel for Disclosures
The Board authorized the following Key Managerial Personnel (KMP) to determine materiality and make disclosures, effective April 01, 2026:
| S. No | Name | Designation |
| 1. | Ms. Kiran Mazumdar-Shaw | Executive Chairperson |
| 2. | Mr. Shreehas Pradeep Tambe | Chief Executive Officer and Managing Director |
| 3. | Mr. Kedar Narayan Upadhye | Chief Financial Officer |
| 4. | Mr. Akhilesh Nand | Head, Governance, Risk and Compliance |
| 5. | Mr. Rajesh Umakant Shanoy | Company Secretary |
The Board Meeting commenced at 10:50 A.M. and concluded at 11:35 A.M.
Profile Highlights for Key Appointees
The document includes brief profiles for the incoming leaders:
Shreehas Tambe (New MD & CEO): Joined Biocon nearly three decades ago. As CEO & MD of Biocon Biologics, he drove the company to become one of the Top 5 biosimilar companies by revenue (valuation of USD 5.5 billion in 2025). He led the acquisition of Viatris’ biosimilars business. He holds a Master’s degree in Bioprocess Technology.
Kedar Narayan Upadhye (New CFO): Brings over 23 years of global leadership experience. At Biocon Biologics, he was instrumental in the $800 million bond issuance listed on the Singapore Exchange. He previously served as CFO for ReNew Energy Global Plc.
Akhilesh Nand (New KMP): Responsible for leading global governance functions. He has 25 years of multi-industry experience and was instrumental in major M&A deals, including Biocon’s acquisition of Viatris’ global biosimilars business.
Naveen Narayanan (New CHRO): Has 25 years of experience across various sectors, including leading HR consulting and transformation initiatives. He served as CHRO of Biocon Biologics since September 2021.
Mandar Shrikant Ghatnekar (New CTO): Has over two decades of advisory and consulting experience in the life sciences industry, focusing on digital and automation technologies. He holds a Ph.D. (Tech).
Source: BSE
